KDR and bone sarcoma: The addition of clinically available mTOR inhibitors (temsirolimus, everolimus, and ridaforolimus) to an angiogenesis inhibitor may be a useful approach in extending the proven activity of VEGFR inhibition in patients with soft tissue or bone sarcomas that have previously responded to VEGFR inhibition.